Orally Disintegrating Tablets: Formulation Strategies, Evaluation Parameters, Manufacturing Technologies and Future Perspectives

Abstract

Orally disintegrating tablets (ODTs), also known as orodispersible, mouth-dissolving or fast-disintegrating tablets, are patient-centric solid oral dosage forms designed to disintegrate rapidly in the oral cavity with saliva and without the need for water. They are particularly useful for pediatric, geriatric, psychiatric, travelling and dysphagic patients, and for therapeutic situations where rapid onset, convenience and improved compliance are desired. The performance of an ODT depends on the physicochemical properties of the active pharmaceutical ingredient, the concentration and mechanism of the superdisintegrant, the solubility and mouthfeel of excipients, tablet porosity, compression force, taste-masking strategy and packaging protection. This review manuscript summarizes the concept, advantages, limitations, formulation components, mechanisms of disintegration, manufacturing technologies, patented platforms, quality-control evaluation parameters, stability concerns and future perspectives of ODTs. Direct compression remains the most widely used method because of its simplicity, economy and scalability; however, technologies such as lyophilization, molding, sublimation, spray drying, melt granulation, cotton-candy process and three-dimensional printing provide additional opportunities for drugs with special requirements. Evaluation of ODTs should include pre-compression and post-compression parameters, especially weight variation, hardness, friability, wetting time, water-absorption ratio, in-vitro disintegration time, dispersion behavior, drug content, dissolution profile, taste acceptability and stability. Modern ODT development increasingly uses quality-by-design, risk assessment, design of experiments, artificial-intelligence assisted formulation screening and personalized manufacturing. Overall, ODTs represent a valuable and expanding dosage-form platform capable of improving patient adherence and therapeutic performance when formulation and process variables are scientifically optimized.

Introduction

Orally Disintegrating Tablets (ODTs) are solid dosage forms designed to rapidly disintegrate in the mouth without the need for water, making them especially beneficial for pediatric, geriatric, dysphagic, bedridden, and psychiatric patients. They improve patient compliance, convenience, and may provide faster drug action compared to conventional tablets. However, developing ODTs is challenging because they must combine rapid disintegration with sufficient mechanical strength, pleasant taste, stability, and manufacturability.

The significance of ODTs lies in their ability to improve medication adherence, patient comfort, and therapeutic outcomes while offering pharmaceutical companies opportunities for product lifecycle enhancement. An ideal ODT should disintegrate within approximately 30 seconds, possess adequate hardness, provide good palatability, ensure dose uniformity, and remain stable under normal storage conditions.

Drug selection plays a vital role in ODT formulation. Suitable candidates are generally low-dose, chemically stable drugs with acceptable taste or effective taste-masking options. Poorly soluble or moisture-sensitive drugs require specialized formulation approaches to achieve rapid dissolution and maintain stability.

ODT formulations contain the active pharmaceutical ingredient along with excipients such as superdisintegrants, diluents, binders, lubricants, sweeteners, flavors, and taste-masking agents. Superdisintegrants like crospovidone, croscarmellose sodium, and sodium starch glycolate are essential for promoting rapid tablet breakup through mechanisms including swelling, wicking, deformation recovery, particle repulsion, and effervescence.

Several manufacturing technologies are employed for ODT production. Direct compression is the most widely used due to its simplicity and cost-effectiveness, while advanced techniques such as lyophilization, molding, sublimation, spray drying, melt granulation, and 3D printing provide faster disintegration or personalized dosage forms. Commercial technologies such as Zydis, OraSolv, DuraSolv, WowTab, and FlashDose further enhance ODT performance through innovative manufacturing approaches.

Finally, ODTs are evaluated using pre-compression and post-compression quality parameters, including powder flow properties, hardness, friability, disintegration time, dissolution, content uniformity, and stability, ensuring that the final product meets pharmaceutical quality standards while delivering rapid, safe, and effective drug administration.

Conclusion

Orally disintegrating tablets are a valuable patient-friendly dosage form that combines the stability and dose accuracy of solid tablets with the convenience of administration without water. They are particularly useful for pediatric, geriatric, dysphagic, psychiatric and travelling patients, and in therapeutic situations where rapid administration is desirable. Successful ODT formulation requires careful balancing of rapid disintegration, mechanical strength, palatability, drug release, stability and manufacturing feasibility. Superdisintegrants are central to ODT performance, but their selection and concentration must be optimized with fillers, binders, lubricants, sweeteners, flavors and taste-masking systems. Direct compression remains the most practical manufacturing approach, while lyophilization, molding, sublimation, spray drying, patented platforms and 3D printing offer specialized advantages. Evaluation should include conventional tablet tests as well as ODT-specific tests such as wetting time, water absorption ratio, disintegration time, dispersion behavior, taste and mouthfeel.

References

[1] U.S. Food and Drug Administration. Guidance for Industry: Orally Disintegrating Tablets. Center for Drug Evaluation and Research (CDER); 2008. [2] Ghourichay MP, Kiaie SH, Nokhodchi A, Javadzadeh Y. Formulation and quality control of orally disintegrating tablets (ODTs): recent advances and perspectives. BioMed Research International. 2021;2021:6638785. [3] Parkash V, Maan S, Deepika, Yadav SK, Hemlata, Jogpal V. Fast disintegrating tablets: opportunity in drug delivery system. Journal of Advanced Pharmaceutical Technology & Research. 2011;2(4):223-235. [4] Dey P, Maiti S. Orodispersible tablets: a new trend in drug delivery. Journal of Natural Science, Biology and Medicine. 2010;1(1):2-5. [5] Yapar EA. Orally disintegrating tablets: an overview. Journal of Applied Pharmaceutical Science. 2014;4(2):118-125. [6] Desai PM, Liew CV, Heng PWS. Review of disintegrants and the disintegration phenomena. Journal of Pharmaceutical Sciences. 2016;105(9):2545-2555. [7] Desai PM, Er PXH, Liew CV, Heng PWS. Functionality of disintegrants and their mixtures in enabling fast disintegration of tablets by a quality by design approach. AAPS PharmSciTech. 2014;15(5):1093-1104. [8] Kumar A, Sahoo SK, Padhee K, Kochar PPS, Sathapathy A, Pathak N. Formulation and evaluation of orally disintegrating tablets using superdisintegrants. Journal of Pharmaceutics. 2017;2017:7018636. [9] Sharma S, Gupta GD. Formulation and characterization of fast-dissolving tablet of promethazine theoclate. Asian Journal of Pharmaceutics. 2008;2(1):70-72. [10] Bhowmik D, Chiranjib B, Krishnakanth P, Chandira RM. Fast dissolving tablet: an overview. Journal of Chemical and Pharmaceutical Research. 2009;1(1):163-177. [11] Dobetti L. Fast-melting tablets: developments and technologies. Pharmaceutical Technology Europe. 2001;13(6):44-50. [12] Chang RK, Guo X, Burnside BA, Couch RA. Fast-dissolving tablets. Pharmaceutical Technology. 2000;24(6):52-58. [13] Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. Journal of Pharmacy and Pharmacology. 1998;50(4):375-382. [14] Kuchekar BS, Badhan AC, Mahajan HS. Mouth dissolving tablets: a novel drug delivery system. Pharma Times. 2003;35(1):7-9. [15] Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: a review. Tropical Journal of Pharmaceutical Research. 2009;8(2):161-172. [16] Velmurugan S, Vinushitha S. Oral disintegrating tablets: an overview. International Journal of Chemical and Pharmaceutical Sciences. 2010;1(2):1-12. [17] Kumari S, Visht S, Sharma PK, Yadav RK. Fast dissolving drug delivery system: review article. Journal of Pharmacy Research. 2010;3(6):1444-1449. [18] International Council for Harmonisation. ICH Q8(R2): Pharmaceutical Development. ICH Harmonised Guideline; 2009. [19] International Council for Harmonisation. ICH Q9(R1): Quality Risk Management. ICH Harmonised Guideline; 2023. [20] International Council for Harmonisation. ICH Q10: Pharmaceutical Quality System. ICH Harmonised Guideline; 2008. [21] Han R, Yang Y, Li X, Ouyang D. Predicting oral disintegrating tablet formulations by neural network techniques. Asian Journal of Pharmaceutical Sciences. 2018;13(4):336-342. [22] Hellberg E, Westberg S, Appelblad P, Mattsson S. Evaluation of dissolution techniques for orally disintegrating mini-tablets. European Journal of Pharmaceutics and Biopharmaceutics. 2021;165:92-101. [23] Moradikouchi A, Sparén A, Folestad S, Stake J, Rodilla H. Terahertz frequency domain sensing for fast porosity measurement of pharmaceutical tablets. International Journal of Pharmaceutics. 2022;615:121466. [24] Jacob S, Nair AB, Shah J. Emerging approaches in patient-centric oral dosage forms. Pharmaceutics. 2023;15(1):224. [25] Abay FB, Ugurlu T. Orally disintegrating tablets: a short review. Journal of Pharmaceutics & Drug Development. 2015;3(3):303. [26] Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Critical Reviews in Therapeutic Drug Carrier Systems. 2004;21(6):433-475. [27] Habib W, Khankari RK, Hontz J. Fast-dissolve drug delivery systems. Critical Reviews in Therapeutic Drug Carrier Systems. 2000;17(1):61-72. [28] Bandari S, Mittapalli RK, Gannu R, Rao YM. Orodispersible tablets: an overview. Asian Journal of Pharmaceutics. 2008;2(1):2-11. [29] Shukla D, Chakraborty S, Singh S, Mishra B. Mouth dissolving tablets I: an overview of formulation technology. Scientia Pharmaceutica. 2009;77(2):309-326. [30] Badgujar BP, Mundada AS. The technologies used for developing orally disintegrating tablets: a review. Acta Pharmaceutica. 2011;61(2):117-139. [31] Bi Y, Sunada H, Yonezawa Y, Danjo K, Otsuka A, Iida K. Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity. Chemical & Pharmaceutical Bulletin. 1996;44(11):2121-2127. [32] Bi Y, Sunada H, Yonezawa Y, Danjo K. Evaluation of rapidly disintegrating tablets prepared by a direct compression method. Drug Development and Industrial Pharmacy. 1999;25(5):571-581. [33] Watanabe Y, Koizumi K, Zama Y, Kiriyama M, Matsumoto Y, Matsumoto M. New compressed tablet rapidly disintegrating in saliva in the mouth using crystalline cellulose and low-substituted hydroxypropylcellulose. Biological & Pharmaceutical Bulletin. 1995;18(9):1308-1310. [34] Abdelbary G, Eouani C, Prinderre P, Joachim J, Reynier JP, Piccerelle P. Determination of the in vitro disintegration profile of rapidly disintegrating tablets and correlation with oral disintegration. International Journal of Pharmaceutics. 2005;292(1-2):29-41. [35] Narazaki R, Harada T, Takami N, Kato Y, Ohwaki T. A new method for disintegration studies of rapid disintegrating tablets. Chemical & Pharmaceutical Bulletin. 2004;52(6):704-707. [36] Ishikawa T, Watanabe Y, Utoguchi N, Matsumoto M. Preparation and evaluation of tablets rapidly disintegrating in saliva containing bitter-taste-masked granules by the compression method. Chemical & Pharmaceutical Bulletin. 1999;47(10):1451-1454.

Copyright

Copyright © 2026 Rushikesh Nikam, Prof. Vinayak Munde. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.